Fertility-sparing therapy for young women with endometrial cancer.
Approximately 1600 women under the age of 40 will be diagnosed with endometrial cancer this year. For these women, preservation of fertility may be one of the most important factors when seeking treatment options. The objective of this article is to review the available literature on fertility-sparing therapy for young women with endometrial cancer. Patient selection, pretreatment testing, treatment regimens, response rates and pregnancy outcomes will be explored. Recommendations regarding this approach for the treatment of endometrial cancer in young women will also be made.
Frumovitz
Michael
M
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. mfrumovitz@mdanderson.org
Gershenson
David M
DM
D000328:Adult; D017668:Age of Onset; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000517:prevention & control*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D019290:Megestrol Acetate / Q000627:therapeutic use; D018579:Patient Selection; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis
D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate; D019290:Megestrol Acetate